Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARN-75039 in Healthy Adult Subjects
NCT05735249Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Lassa fever (LASV) comparing ARN-75039 oral capsules with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 39 and Incidence of Treatment-Emergent Serious Adverse Events at Day 39. Started Jan 2023; status: completed.
02
Drugs
ARN-75039
03
Conditions
Lassa fever (LASV)
Beyond the preview
Go deeper on NCT05735249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735249.